Run Sheng Jiang

President presso WALVAX BIOTECHNOLOGY CO., LTD.

Patrimonio netto: 4 M $ in data 31/03/2024

67 anni

Health Technology

Profilo

Run Sheng Jiang occupa la posizione di Presidente e Direttore di Walvax Biotechnology Co., Ltd. e Presidente di Shanghai Zerun Biotech Co. (una filiale di Walvax Biotechnology Co., Ltd.).

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
WALVAX BIOTECHNOLOGY CO., LTD. CLASS A 0.06%	30/06/2023	930 000 ( 0.06% )	2 M $	31/03/2024
WALVAX BIOTECHNOLOGY CO., LTD. 1.64%	30/09/2023	773 437 ( 1.64% )	2 M $	31/03/2024

Posizioni attive di Run Sheng Jiang

Società	Posizione	Inizio
WALVAX BIOTECHNOLOGY CO., LTD.	President	22/06/2016
Shanghai Zerun Biotechnology Co., Ltd. Shanghai Zerun Biotechnology Co., Ltd. BiotechnologyHealth Technology Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China.	Chairman	-

Tutte le posizioni attive di Run Sheng Jiang

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Run Sheng Jiang

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
WALVAX BIOTECHNOLOGY CO., LTD.	Health Technology

Aziende private	1
Shanghai Zerun Biotechnology Co., Ltd. Shanghai Zerun Biotechnology Co., Ltd. BiotechnologyHealth Technology Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China.	Health Technology